Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?

The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. A literature search through the Medline database and Google was conducted. Articles published up to September 20...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of clinical psychiatry 2007-04, Vol.19 (2), p.133-143
Hauptverfasser:	Motlová, Lucie, Spaniel, Filip, Höschl, Cyril, Balon, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Humans Neuropsychological Tests Psychiatric Status Rating Scales Randomized Controlled Trials as Topic Schizophrenia - diagnosis Schizophrenia - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	143
container_issue	2
container_start_page	133
container_title	Annals of clinical psychiatry
container_volume	19
creator	Motlová, Lucie Spaniel, Filip Höschl, Cyril Balon, Richard
description	The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.
doi_str_mv	10.1080/10401230701334606
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20635768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20635768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-21bbb4a7a546072daaccb1aff0630a4c04fc09cb850d7b2b6e51a676843091a73</originalsourceid><addsrcrecordid>eNplkLtOBDEMRSME4v0BNCgV3YAzmUxmK4QQLwmJBuqRJ-OwQTvJkmSL5Q_4a4JYQUFjW_I91_Jl7ETAuYAOLgQ0IGoJGoSUTQvtFtsXqtGVlLXaLnPZV0Wg99hBSm8AMGs7tcv2hG5F3Sm5zz6vIvE8p1LRr_norC2zN5S4898LTtY6g2bNcQr-lScywY_8lTxFzC74wmW3TGszD9mZXyxHwjyRzzxYnszcfYTlvDg7LMDIIy0w01gOphBHiunyiO1YXCQ63vRD9nJ783x9Xz0-3T1cXz1Wpm5UrmoxDEODGlV5WNcjojGDQGuhlYCNgcYamJmhUzDqoR5aUgJb3XaNhJlALQ_Z2Y_vMob3FaXcTy4ZWizQU1ilvi5GquiLUPwITQwpRbL9MroJ47oX0H_n3__LvzCnG_PVMNH4R2wCl1_Ns4K5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20635768</pqid></control><display><type>article</type><title>Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?</title><source>CLOCKSS</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Portico (Triggered Content) Journals</source><creator>Motlová, Lucie ; Spaniel, Filip ; Höschl, Cyril ; Balon, Richard</creator><creatorcontrib>Motlová, Lucie ; Spaniel, Filip ; Höschl, Cyril ; Balon, Richard</creatorcontrib><description>The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</description><identifier>ISSN: 1040-1237</identifier><identifier>EISSN: 1547-3325</identifier><identifier>EISSN: 1573-3238</identifier><identifier>DOI: 10.1080/10401230701334606</identifier><identifier>PMID: 17612853</identifier><language>eng</language><publisher>United States</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Humans ; Neuropsychological Tests ; Psychiatric Status Rating Scales ; Randomized Controlled Trials as Topic ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Treatment Outcome</subject><ispartof>Annals of clinical psychiatry, 2007-04, Vol.19 (2), p.133-143</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c245t-21bbb4a7a546072daaccb1aff0630a4c04fc09cb850d7b2b6e51a676843091a73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17612853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Motlová, Lucie</creatorcontrib><creatorcontrib>Spaniel, Filip</creatorcontrib><creatorcontrib>Höschl, Cyril</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><title>Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?</title><title>Annals of clinical psychiatry</title><addtitle>Ann Clin Psychiatry</addtitle><description>The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Humans</subject><subject>Neuropsychological Tests</subject><subject>Psychiatric Status Rating Scales</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Treatment Outcome</subject><issn>1040-1237</issn><issn>1547-3325</issn><issn>1573-3238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkLtOBDEMRSME4v0BNCgV3YAzmUxmK4QQLwmJBuqRJ-OwQTvJkmSL5Q_4a4JYQUFjW_I91_Jl7ETAuYAOLgQ0IGoJGoSUTQvtFtsXqtGVlLXaLnPZV0Wg99hBSm8AMGs7tcv2hG5F3Sm5zz6vIvE8p1LRr_norC2zN5S4898LTtY6g2bNcQr-lScywY_8lTxFzC74wmW3TGszD9mZXyxHwjyRzzxYnszcfYTlvDg7LMDIIy0w01gOphBHiunyiO1YXCQ63vRD9nJ783x9Xz0-3T1cXz1Wpm5UrmoxDEODGlV5WNcjojGDQGuhlYCNgcYamJmhUzDqoR5aUgJb3XaNhJlALQ_Z2Y_vMob3FaXcTy4ZWizQU1ilvi5GquiLUPwITQwpRbL9MroJ47oX0H_n3__LvzCnG_PVMNH4R2wCl1_Ns4K5</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>Motlová, Lucie</creator><creator>Spaniel, Filip</creator><creator>Höschl, Cyril</creator><creator>Balon, Richard</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200704</creationdate><title>Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?</title><author>Motlová, Lucie ; Spaniel, Filip ; Höschl, Cyril ; Balon, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-21bbb4a7a546072daaccb1aff0630a4c04fc09cb850d7b2b6e51a676843091a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Humans</topic><topic>Neuropsychological Tests</topic><topic>Psychiatric Status Rating Scales</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Motlová, Lucie</creatorcontrib><creatorcontrib>Spaniel, Filip</creatorcontrib><creatorcontrib>Höschl, Cyril</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Annals of clinical psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Motlová, Lucie</au><au>Spaniel, Filip</au><au>Höschl, Cyril</au><au>Balon, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?</atitle><jtitle>Annals of clinical psychiatry</jtitle><addtitle>Ann Clin Psychiatry</addtitle><date>2007-04</date><risdate>2007</risdate><volume>19</volume><issue>2</issue><spage>133</spage><epage>143</epage><pages>133-143</pages><issn>1040-1237</issn><eissn>1547-3325</eissn><eissn>1573-3238</eissn><abstract>The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</abstract><cop>United States</cop><pmid>17612853</pmid><doi>10.1080/10401230701334606</doi><tpages>11</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1040-1237
ispartof	Annals of clinical psychiatry, 2007-04, Vol.19 (2), p.133-143
issn	1040-1237 1547-3325 1573-3238
language	eng
recordid	cdi_proquest_miscellaneous_20635768
source	CLOCKSS; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Portico (Triggered Content) Journals
subjects	Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Humans Neuropsychological Tests Psychiatric Status Rating Scales Randomized Controlled Trials as Topic Schizophrenia - diagnosis Schizophrenia - drug therapy Treatment Outcome
title	Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T04%3A37%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20there%20any%20differences%20in%20the%20efficacy%20among%20second%20generation%20antipsychotics%20in%20the%20treatment%20of%20schizophrenia%20and%20related%20disorders?&rft.jtitle=Annals%20of%20clinical%20psychiatry&rft.au=Motlov%C3%A1,%20Lucie&rft.date=2007-04&rft.volume=19&rft.issue=2&rft.spage=133&rft.epage=143&rft.pages=133-143&rft.issn=1040-1237&rft.eissn=1547-3325&rft_id=info:doi/10.1080/10401230701334606&rft_dat=%3Cproquest_cross%3E20635768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20635768&rft_id=info:pmid/17612853&rfr_iscdi=true